245 related articles for article (PubMed ID: 32590358)
1. Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
Grozinsky-Glasberg S; Lines KE; Avniel-Polak S; Bountra C; Thakker RV
Endocr Relat Cancer; 2020 Sep; 27(9):R345-R355. PubMed ID: 32590358
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging therapies for PNETs in patients with or without MEN1.
Frost M; Lines KE; Thakker RV
Nat Rev Endocrinol; 2018 Apr; 14(4):216-227. PubMed ID: 29449689
[TBL] [Abstract][Full Text] [Related]
3. [Inherited tumor syndromes of gastroenteropancreatic and thoracic neuroendocrine neoplasms].
Couvelard A; Scoazec JY
Ann Pathol; 2020 Apr; 40(2):120-133. PubMed ID: 32035641
[TBL] [Abstract][Full Text] [Related]
4. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs).
Effraimidis G; Knigge U; Rossing M; Oturai P; Rasmussen ÅK; Feldt-Rasmussen U
Semin Cancer Biol; 2022 Feb; 79():141-162. PubMed ID: 33905872
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review.
La Salvia A; Sesti F; Grinzato C; Mazzilli R; Tarsitano MG; Giannetta E; Faggiano A
Pharmaceuticals (Basel); 2021 Oct; 14(10):. PubMed ID: 34681263
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
[TBL] [Abstract][Full Text] [Related]
7. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
8. What is the appropriate management of nonfunctioning pancreatic neuroendocrine tumours disclosed on screening in adult patients with multiple endocrine neoplasia type 1?
Challis BG; Casey RT; Grossman A; Newell-Price J; Newey P; Thakker RV
Clin Endocrinol (Oxf); 2019 Dec; 91(6):708-715. PubMed ID: 31505044
[TBL] [Abstract][Full Text] [Related]
9. Glucagon expression in cystic pancreatic neuroendocrine neoplasms: an immunohistochemical analysis.
Konukiewitz B; Enosawa T; Klöppel G
Virchows Arch; 2011 Jan; 458(1):47-53. PubMed ID: 20922407
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of clinical features between sporadic pancreatic neuroendocrine tumors and those associated with multiple endocrine neoplasia type 1].
Gu DY; Fu Q; Xue BY; Kan JB; Bai JA; Tang QY
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):1014-1019. PubMed ID: 35399021
[No Abstract] [Full Text] [Related]
11. Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1.
Jhawar S; Lakhotia R; Suzuki M; Welch J; Agarwal SK; Sharretts J; Merino M; Ahlman M; Blau JE; Simonds WF; Del Rivero J
Endocrinol Diabetes Metab Case Rep; 2019 Aug; 2019():. PubMed ID: 31480016
[TBL] [Abstract][Full Text] [Related]
12. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
Ramundo V; Del Prete M; Marotta V; Marciello F; Camera L; Napolitano V; De Luca L; Circelli L; Colantuoni V; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A;
Clin Endocrinol (Oxf); 2014 Jun; 80(6):850-5. PubMed ID: 24443791
[TBL] [Abstract][Full Text] [Related]
13. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1.
Yates CJ; Newey PJ; Thakker RV
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):895-905. PubMed ID: 26165399
[TBL] [Abstract][Full Text] [Related]
14. Multiple endocrine neoplasia type 1.
Marini F; Falchetti A; Del Monte F; Carbonell Sala S; Gozzini A; Luzi E; Brandi ML
Orphanet J Rare Dis; 2006 Oct; 1():38. PubMed ID: 17014705
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1).
Gaztambide S; Vazquez F; Castaño L
Minerva Endocrinol; 2013 Mar; 38(1):17-28. PubMed ID: 23435440
[TBL] [Abstract][Full Text] [Related]
16. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias.
Marx SJ; Agarwal SK; Kester MB; Heppner C; Kim YS; Skarulis MC; James LA; Goldsmith PK; Saggar SK; Park SY; Spiegel AM; Burns AL; Debelenko LV; Zhuang Z; Lubensky IA; Liotta LA; Emmert-Buck MR; Guru SC; Manickam P; Crabtree J; Erdos MR; Collins FS; Chandrasekharappa SC
Recent Prog Horm Res; 1999; 54():397-438; discussion 438-9. PubMed ID: 10548885
[TBL] [Abstract][Full Text] [Related]
17. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors.
Kfir SK; Halperin R; Percik R; Uri I; Halpern N; Shlomai G; Laish I; Tirosh A; Tirosh A
Horm Metab Res; 2021 May; 53(5):319-325. PubMed ID: 33878789
[TBL] [Abstract][Full Text] [Related]
18. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
19. Multiple endocrine neoplasia type 1: extensive analysis of a large database of Florentine patients.
Marini F; Giusti F; Brandi ML
Orphanet J Rare Dis; 2018 Nov; 13(1):205. PubMed ID: 30428914
[TBL] [Abstract][Full Text] [Related]
20. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.
Pieterman CR; Conemans EB; Dreijerink KM; de Laat JM; Timmers HT; Vriens MR; Valk GD
Endocr Relat Cancer; 2014 Jun; 21(3):R121-42. PubMed ID: 24389729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
